Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06988488 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Celgene.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 20
- Study locations
NCT06988488: Recruiting Phase 1 study of Multiple Myeloma, sponsored by Celgene.
NCT06988488 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Celgene. The registered enrollment target is 62 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06988488, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Celgene.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Elranatamab
- DRUG Mezigdomide
Study Locations (20)
Other
- Universitaetsklinikum Carl Gustav Carus Dresden - Dresden
- Universitaetsklinikum Hamburg-Eppendorf - Hamburg
- Universitaetsklinikum Heidelberg - Heidelberg
- Sykehusapoteket Ull - Oslo
- Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca - Salamanca
Attikí
- Evangelismos General Hospital of Athens - Athens
- Alexandra General Hospital of Athens - Athens
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale New Haven Hospital-Smilow Cancer Center - New Haven
New Jersey
- Hackensack University Medical Center - Hackensack
Texas
- University of Texas MD Anderson Cancer Center - Houston
Alberta
- Arthur J E Child Comprehensive Cancer Centre - Calgary
British Columbia
- Local Institution - 0026 - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2027-06-03 |
| Phase | Phase 1 |
What NCT06988488 shows while recruiting
NCT06988488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT06988488 names 20 study sites across 15 states, led by Other, Attikí, Alabama.
Frequently Asked Questions
What is clinical trial NCT06988488 about?
NCT06988488 is a clinical study titled "A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma". The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
What is the current status of trial NCT06988488?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2025-10-07. Estimated completion is 2027-06-03.
What conditions does trial NCT06988488 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06988488?
The interventions under investigation include: Dexamethasone (DRUG), Elranatamab (DRUG), Mezigdomide (DRUG).
Who is sponsoring clinical trial NCT06988488?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06988488 being conducted?
This trial has 20 study locations across Alabama, Connecticut, New Jersey, Texas, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06988488's enrollment target sits among peer trials
62 224th of 438 higher than 214 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI